This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.
Subscribe to the Daily Journal for access to Daily Appellate Reports, Verdicts, Judicial Profiles and more...

Transactions

Dec. 19, 2000

Latham & Watkins: GENOMICS DEVELOPER PLANS FOR INITIAL PUBLIC OFFERING

Santa Clara's diaDexus Inc. has filed for an initial public offering valued at $100 million. DiaDexus, founded by genomics companies SmithKline Beecham Corp. and Incyte Genomics Inc. in 1997, discovers and develops novel genomic biomarkers that have the potential of detecting diseases in individuals before they experience any symptoms. The company has 37 biomarkers in development, most of which will target cancer detection.

        Santa Clara's diaDexus Inc. has filed for an initial public offering valued at $100 million.
        DiaDexus, founded by genomics companies SmithKline Beecham Corp. and Incyte Genomics Inc. in 1997, discovers and develops novel genomic biomarkers that have the potential of detecting diseases in individuals before they experience any symptoms. The company has 37 biomarkers in developme...

To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!

Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)

Already a subscriber?

Enewsletter Sign-up